Amy Spallone, M.D.

University of Texas MD Anderson Cancer Center

Disclosure(s): No financial relationships to disclose

Poster(s):

• (P-694) Outcomes of respiratory viral infections in hematopoietic cell transplant recipients and patients with leukemia: a prospective study.
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-726) "Infectious Complications in Patients with Relapsed/Refractory Multiple Myeloma Undergoing Novel Bispecific Antibody Therapy: A Myeloma-Infectious Disease Database Initiative"
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-729) Prognostic Value of the Immunodeficiency Scoring Index for Respiratory Viral Infections in Hematopoietic Cell Transplant Recipients
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-730) Risk Factors for Severe Influenza and Respiratory Syncytial Virus Infections in Patients with Lymphoma or Multiple Myeloma - A Seven-Year Retrospective Cohort Study
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-1013) Incidence and Risk Factors for Fungal Infection after CD19-targeted Chimeric Antigen Receptor T cell Therapy for Non-Hodgkin Lymphoma
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1094) Real-World Experience with Maribavir for the Treatment of Cytomegalovirus Infection in Patients with Hematologic Malignancies
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-2297) Evaluation of a Meta-Virus Signature as a Diagnostic Tool to Predict the Severity of Respiratory Viral Infections in Hematopoietic Cell Transplant Recipients
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT